HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MSM Nutraceuticals Ends 'Drug' Production, Warned On Claims, Ingredients

Executive Summary

MSM Nutraceuticals may opt to use contract manufactures to resume marketing MSM-containing products. When it does, the firm is warned not to label and market its “MSM Pain Gel" and "MSM Nasal Spray" products as drugs.

You may also be interested in...



ED-Spiked Honey Among Latest Consumer Health Recalls

Latest updates to FDA's recalls list also includes four OTC eye drop products from MSM Nutraceuticals the agency says are not terminally sterilized and not tested per US Pharmacopeia standards, and Estee Lauder Clinique Laboratories brand Repairwear Laser Focus Line Smoothing Cream Broad Spectrum SPF 15 due to a defective container.

FDA Combines Supplement GMP Recordkeeping, Testing Waiver Estimates

FDA didn't change its estimates for industry's annual regulatory burden – 929,140 hours – from compliance with recordkeeping requirements in supplement GMPs, its estimates of eight hours needed to prepare a request for exemption from identity-testing requirement also in unchanged.

On CRN Challenge, Nexus Formulas Gets Lesson On Supporting Ad Claims For Supplements

So full of errors were the firm's online ads for its Plavinol supplement, the National Advertising Division noted support for some claims contained "many of the same flaws" as others. The prevalence of problems prompted NAD to go outside its "scope of review" and note unclear instructions on Plavinol labels.

Topics

UsernamePublicRestriction

Register

RS149411

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel